Mavacamten Therapy for Obstructive HCM — Do Women Respond Differently Than Men?

A subgroup analysis of a large, randomized trial shows similar clinical outcomes by patient sex.

Observational studies of individuals with hypertrophic cardiomyopathy (HCM) have identified sex differences in disease manifestations and outcomes, with women typically presenting with more advanced symptoms, more severe left ventricular outflow obstruction, and higher mortality rates. In this prespecified subgroup analysis of the manufacturer-sponsored EXPLORER-HCM study (NEJM JW Cardiol Aug 30 2020 and Lancet 2020; 396:759), the investigators assessed differences in clinical outcomes between women and men who received the cardiac myosin ATPase inhibitor mavacamten for treatment of symptomatic obstructive HCM.

The analysis included 102 women (mean age, 62 years; New York Heart Association [NYHA] class III, 42%; peak VO₂, 16.7 mL/kg/min; bas…

Reviewing Author

Frederick A. Masoudi, MD, MSPH, MACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)